Skip to main content
S&P 5007,683.69-0.77%DOW51,481.51-0.67%NASDAQ26,820.38-0.92%GOLD$4,187.90+0.47%OIL$90.47-2.30%
Delayed
Smart Investors Daily
OS

NYSE · OSTX

OS Therapies Incorporated

Healthcare · Biotechnology

$1.65

Down-$0.02 (-0.90%)

Updated Sep 29, 2026, 12:19 PM

SID Score

4.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
71.66M
P/E ratio
-0.01
Dividend yield
0.00%
52-week range
$1.15 – $2.25
Volume
353.42K
Avg. volume
342.06K

Price performance · OSTX

OSTX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 28, 2026

OSTX closed at $1.65 after 20 trading sessions, down 2.37% for the selected period.

Last close
$1.65
Period change
-2.37%
Period low
$1.65
Period high
$1.88
Daily close
View OHLC price history
OSTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 28, 2026$1.66$1.6792$1.61$1.65353.42K
Sep 25, 2026$1.67$1.68$1.64$1.66171.42K
Sep 24, 2026$1.66$1.67$1.615$1.66347.76K
Sep 23, 2026$1.76$1.77$1.64$1.65654.5K
Sep 22, 2026$1.76$1.84$1.74$1.77600.39K
Sep 21, 2026$1.81$1.815$1.74$1.74637.06K
Sep 18, 2026$1.81$1.83$1.76$1.77908.58K
Sep 17, 2026$1.80$2.00$1.80$1.832.23M
Sep 16, 2026$1.79$1.82$1.74$1.75421.33K
Sep 15, 2026$1.78$1.81$1.71$1.781.05M
Sep 14, 2026$1.65$1.79$1.62$1.70993.72K
Sep 11, 2026$1.81$1.8399$1.66$1.68825.87K
Sep 10, 2026$1.87$1.92$1.81$1.82547.91K
Sep 9, 2026$1.83$1.92$1.80$1.86393.18K
Sep 8, 2026$1.96$2.015$1.7504$1.831.77M
Sep 4, 2026$1.84$1.96$1.84$1.88982.58K
Sep 3, 2026$1.72$1.84$1.72$1.82894.28K
Sep 2, 2026$1.68$1.72$1.61$1.71530.47K
Sep 1, 2026$1.68$1.705$1.63$1.66400.62K
Aug 31, 2026$1.62$1.6901$1.62$1.69234.96K

Latest OSTX news

The latest Smart Investors Daily articles mentioning OSTX.

Stock researchCompany · Overview

OSTX research

Overview

Company profile and research snapshot.

Company profile

OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.01
Implied upside
—
Analysts
10
OSTX recent ratings
DateFirmRatingTarget
Jul 9, 2026Roth CapitalBuy—
May 19, 2026Lake StreetBuy—
Apr 30, 2026D. Boral CapitalBuy—
Apr 8, 2026D. Boral CapitalBuy—
Mar 27, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 21, 2026

OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing Authorisation Application (CMAA) submission in the coming weeks and Phase 3 trial initiation in mid Q4/'26 following Phase 2b drug product requalificationMHRA's SAM participants' recommendation to Project Orbis U.K. leadership to take the global regulatory leadership mantle with U.S. FDA and EMA,...

Yahoo · Sep 17, 2026

OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program

FDA aligns with MHRA and EMA on adaptive design for Phase 3 trialAfter successful Scientific Advice Meeting, OS Therapies accepts MHRA request to become the Company's sponsor into Project Orbis to harmonize regulatory review with FDA and EMACBER recently re-opened Project Orbis to foreign-sponsored U.S. companies onlyNew York, New York and Rockville, Maryland--(Newsfile Corp. - September 17, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in..

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By